News
FB102 First Drug to Beat Placebo in Vitiligo
2+ hour, 24+ min ago (621+ words) All Sci Dallas-based Forte Biosciences, Inc. (Nasdaq: FBRX) has reported statistically significant repigmentation data from a Phase Ib double-blind, placebo-controlled study of FB102 in vitiligo " the first placebo-controlled evidence of efficacy for the anti-CD122 monoclonal antibody in a skin depigmentation disorder....
Oryzon Vafidemstat Patent Extended to 2043
7+ hour, 12+ min ago (797+ words) All Sci Oryzon Genomics (Madrid: ORY), the Barcelona-based epigenetics company, has secured a US Patent (No. 12, 673, 044) covering methods of treating non-aggressive symptoms of borderline personality disorder using LSD1 inhibitors, including vafidemstat (ORY-2001). The grant, issued by the USPTO, is commercially significant…...
Prime Medicine Wins AATD Gene Therapy Arbitration
5+ hour, 26+ min ago (311+ words) The tribunal ruled in Prime's favor on both questions: PM647 is within Prime Medicine's Field, and the company did not breach the agreement. The ruling is binding, and Prime Medicine owes Beam no financial remedy. AATD affects approximately 200, 000 people across the…...
Evogene Partners with Tel Aviv University on AI Drug. ..
1+ day, 2+ hour ago (334+ words) All Sci Israel-based computational chemistry company Evogene Ltd. (Nasdaq: EVGN) and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University have announced a joint initiative to accelerate small-molecule drug discovery for programs originating from Israel's academic research ecosystem....
Seres' SER-155 Resolves Checkpoint Inhibitor Colitis
23+ hour, 39+ min ago (432+ words) All Sci Cambridge, Massachusetts-based Seres Therapeutics (Nasdaq: MCRB) reported early clinical data suggesting that SER-155, its oral live biotherapeutic, may resolve diarrhea associated with immune checkpoint inhibitor-related enterocolitis without requiring systemic immunosuppression " a finding that, if confirmed in larger studies,…...
Astra Zeneca Buys TQC3721 Rights for $2. 1 B
1+ day, 6+ min ago (606+ words) All Sci Astra Zeneca has secured ex-China rights to TQC3721, an inhaled dual PDE3/4 inhibitor for COPD, in a deal worth USD 200 million upfront and up to USD 2. 1 billion in total potential value. The molecule, discovered and developed by Chia Tai Tianqing…...
TERT m RNA Therapy Advances for Alcoholic Hepatitis
1+ day, 7+ min ago (227+ words) All Sci Rejuvenation Technologies, Inc. , a Mountain View, California-based biotechnology company, has received a USD 2. 06 million NIAAA SBIR Commercialization Readiness Pilot grant to advance a TERT m RNA therapeutic toward an IND submission for alcoholic hepatitis " a condition with 2550% one-month…...
Ohio State Develops KRAS-Targeting RNA Nanotechnology
23+ hour, 41+ min ago (380+ words) All Sci Ohio State University has received a USD 1. 43 million NCI R01 grant to develop an exosome-based RNA nanotechnology platform targeting mutant KRAS in metastatic colorectal cancer " one of oncology's most intractable therapeutic challenges, given that KRAS mutations drive roughly 45% of…...
GSK Expands Sino Bio Partnership: $4. 5 B Inhaler Deal
1+ day, 1+ hour ago (230+ words) Financial terms were not disclosed. Under the agreement, CTTQ will purchase finished product from GSK and book China sales revenue, following the same commercialization and supply model used in the earlier bepirovirsen collaboration. The deal follows Trelegy's 2026 China approval in…...
Astra Zeneca Partners with Helix for Drug Discovery
1+ day, 6+ hour ago (344+ words) All Sci Astra Zeneca has signed a multi-year agreement with San Mateo-based Helix to access its Geno Sphere clinico-genomic cohort platform for drug discovery and development, adding a major US commercial data source to its existing population genomics infrastructure. The…...